Table Of Content

ACTH 85, 118, 126-7 control methods, for rodent populations activin 60 biological 274-6 characterization 195-8 chemical 278-301 paracrine actions 209-12 ecological 276 during pregnancy 214-17 genetical 277 structure 193-5 mechanical 273-4 amenorrhoea 113-41 corpus luteum lactational 124-15 secretion of inhibin 200-9, 213 amniotic fluid 321-2, 344 see also luteolysis angiogenesis 11-12 corticotrophin-releasing hormone 118, 126-7, anticoagulant rodenticides 282-91 319-20 anti-oncogene 7-9, 22-3 CRH, see corticotrophin-releasing hormone athletes CSF-1, see colony-stimulating factor body composition 121 cytokine 83-111 menstrual dysfunction 113-41 stress 122-3 see also exercise decidua cytokines 83-111 growth factors 83-111 bait aversion 280, 298-300 delivery 148-51, 165 basal body temperature 85 see also parturition birds, spermatogenesis 233-64 diet blastocyst, see embryo of athletes 120 blood-testis barrier 235-7 effects in animals 127-8 bonding, mother-young 311-64 effects in men 127-8 effects on gonadotrophin release 128-9 effects on oestrogen metabolism 129-31 -erb-A 21 food preferences 348-9 -erb-B 14-16 and menstrual dysfunction 113-41 -fms 17, 64-5 mineral deficiency 120, 124 ligand 12-13 of Third World women 123-4 c-int 10-12 c-kit 65 c-ras 21-2 early pregnancy factor 97-8 c-sis 9-10 embryo catecholoestrogen, see oestrogen cytokines 83-111 cell cycle 9 growth factors 43-71 cervix energy expenditure effectso f prostaglandins 157-8 balance 125-6, 128-9 effects of relaxin 151-8, 166-71 in sport 119-20 a-chlorohydrin 297-8 in work 124 chemosterilant 294-301 EPF, see early pregnancy factor cholecystokinin 340 epidermal growth factor 13-16, 54-9, 66 collagen properties 54—5 effects of relaxin 151-8, 166-71 receptor 13-6, 55-9 colony-stimulating factor-1 12-13, 63-7, erb-B 24 89-90 ethinyl oestradiol 297-8 inembryos 64—5, 89-90 exercise properties 63-4 energy expenditure 119-20, 124, 125-6 receptor. 17, 64-5, 90 and gonadotrophin secretion 113-41 366 Index and melatonin 131 control of 212-13 and menstrual dysfunction 113-41 during pregnancy 214-17 and oestrogen metabolism 129-31 isolation 195-8 extracellular matrix 12 levels 200-9 in the male 218-20 paracrine actions 209-12 FGF, see fibroblast growth factor radioimmunoassay 198-9 fibroblast growth factor 10-12, 60-3, 66, 95 secretion 200-9, 218-20 inembryos 61-3 structure 193-5 properties 60-1 synthesis 193-5 fms 25 insulin 45-54 follicle insulin-like growth factors 13, 45-54, 66, 95 fluids 192-200 binding proteins 47, 52 effects of inhibin 209-12 gene expression 47-52 isolation of inhibin 192-8 properties 45-47 secretion of inhibin 200-9 role in preimplantation embryos 52-4 follicle-stimulating hormone interferons 91-2 and inhibin 191-222 interleukins 12, 65, 83-9 and menstrual cycles 113-41 fos 18-20 FSH, see follicle-stimulating hormone jun 18-20 GM-CSF, see granulocyte macrophage lactation stimulating factor amenorrhoea GnRH, see gonadotrophin-releasing hormone effects of relaxin 161-2, 171-3 gonadotrophin-releasing hormone weaning 343-5 and inhibin 191-222 leukaemia inhibitory factor 65, 67, 95-6 and menstrual cycle dysfunction 118, 127 LH, see luteinizing hormone gossypol acetic acid 297-8 LIF, see leukaemia inhibitory factor O granulocyte macrophage stimulating factor 65, luteinizing hormone 67, 90-1 and inhibin 191-222 growth factors in menstrual cycle 113-41 inembryos 43-81 effects of relaxin 176 and oncogenes 1-42 luteolysis 92 receptors 3-17 at parturition 148, 165 in uterus 1-42, 43-81, 83-111 lymphocytes, and interleukins 84-9 oO see also individual growth factors ol growth hormone 176 guanine nucleotide binding proteins 21 mammary tissue, effects of relaxin 161-3, te 171-3 ol maternal behaviour 311-64 HBGF, see heparin binding growth factor bonding to young 341-5 heparin binding growth factor 11 experience 346 hydatidiform mole 217-18 licking 338-9 hypothalamic—pituitary axis olfactory preferences 322-3 and adrenal 118, 122-3 onset 314-6 and exercise 117-41 preparation for parturition 313-14 olf opioids 126-7 recognition of young 323-31 on and ovary 117-8 responsiveness 342-3 selectivity 323-31, 346-7 vocalizations 332, 335-7 IGF-I, IGF-II, see insulin-like growth factors weaning 343-5 inhibin 60, 191-232 melatonin, in exercise 131 autocrine actions 209-12 menarche 116, 121-2 bioassay 200 menstrual cycle characterization 195-8 dysfunction 113-41 and clinical disorders 217-18 hormone profiles 116—17, 200-9 Index 367 inhibin levels 200-9 opioids in lactation 124-5 and amenorrhoea 126-7 methyl testosterone 297-8 and neonatal learning 340 Mifepristone 300 and parturition 318-20 milk Org 5933 299-300 ejection reflex 174 ovarian failure 217 intake 338 oxytocin 160, 174-5 weaning 343-5 at parturition 317-20 mineral deficiency 120, 124 mother—young bonding 311-64 myc 20-1, 23-4 p53 25 PAF, see platelet-activating factor parturition 316-20 neonate preparation for 313-14 attraction to mother 331-3 site of 347-8 behaviour 331-41 PDGF, see platelet-derived growth factor bonding to mother 335-7, 341-5 pheromone, rodent 281 food preferences 348-9 see also olfactory cues learning 337-41 placenta 15-16 locating teat 334-5 inhibin production 214-17 prenatal experience 339-40 platelet-activating factor 96-7 recognition of mother 348 platelet-derived growth factor 9-10, 59-60, 67, neu 24 96 nipple growth 162-3 inembryos 59-60 nutrition properties 59 and menstrual cycle dysfunction 113-41] polyamines 98-9 see also diet polycystic ovarian disease 218 population control, of rodents 265-310 prenatal experience 339-40 oestrogen progesterone during ovarian cycle 200-9 during ovarian cycle 200-9 during pregnancy 143-78 at parturition 316-20 metabolism 129-131 during pregnancy 143-78 at parturition 316-20 and relaxin 143-78 and relaxin 143-78 prolactin 317 and uterine growth factors 142 prostaglandin E2 98, 157-8 oTP-1, see interferons prostaglandin F2a 92,98 olfaction proto-oncogenes 3-4, 63-5 and maternal behaviour 321-2, 324-31 functional classes 6-7 and vagino-cervical stimulation 328-31 olfactory cues 326-8 amniotic fluid 327, 335 ras 24 dietary 327-8 RB 25 genetically determined 326-7 receptors, for growth factors 3-17, 43-81 in utero 339-40 steroid hormone 18 memory 342-3 thyroid hormone 18, 23 udder 334-5 relaxin 143-89 olfactory preferences 322-3 autocrine effects 173-4 oncogenes 1-42 central effects 174-6 discovery 3-6 chemistry 144-5 growth factor receptors 13-17 effects of antibodies 149-53, 159-63 growth factors 9-13 effects guanine nucleotide binding proteins 21-2 on blood pressure 175 nomenclature 5 on cervix 151-8, 166-71 in retroviruses 3-4 on delivery 148-51, 165 transcription factors 17-21 on mammary tissue 161-4, 171-3 and uterine function 142 on uterine contractility 158-61, 171 see also proto-oncogenes, anti-oncogenes on uterine growth 171 368 Index isolation 144—5 stress secretion, in pigs 164—5 and menstrual dysfunction 113-41 secretion, in rats 146-8 sucking behaviour 340-2 source 144 reproductive strategy 253-5, 292-5 rodent testis chemical attractants 279-82 of birds 234 chemical repellents 278-9 and inhibin production 218-20 chemosterilants 294-301 TGF-a@, see transforming growth factor-a pheromones 281 TGF-B, see transforming growth factor-B rodent populations, 265-310 TNF-a@ and TNF-£, see tumour necrosis factor control 265-310 training, see exercise damage by 265-73 transcription factor 17-21 and human economy 270-2 transforming growth factor-a 14, 54-7, 67, 87, and human health 267-70 93-4 see also control methods transforming growth factor-B 60-3, 67, 94-5, rodenticides 282-91 192, 198 RU 486, see Mifepristone inembryos 61-3 properties 60-1 in uterus 94—5 seminiferous tubule 233-56 trophoblast sensitive period growth factors 43-68, 83-99 induction of maternal behaviour 314-16 inhibin production 214 Sertoli cells 235-7, 244 tumour necrosis factor 93 sperm tumour suppressors 22-3 maturation 240-3 production 253-5 spermatid uterus development 240, 244-7 cancer 23-5 spermatocytes cytokines 83-111 primary 238, 244-7 growth factors 1-42, 43-81, 83-111 secondary 238-40, 244-7 oncogenes 1-42 spermatogenesis effects of relaxin 158-61, 171 in birds 233-64 cellular associations 244-6 cycle of 246-7 vagino-cervical stimulation 317-20, 322-3 duration 251-2 and olfactory recognition 328-31 regulation 252-3 vasopressin 175 wave 248-9 spermatogonia 237-8, renewal 249-5] weaning 343-5 spermatozoa 240-4 Wilms’ tumour 8, 22-3 spermiation 240-3 WTI, see Wilms’ tumour 29 14)